Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Sehn LH. A decade of R-CHOP. Blood 2010;116:2000–2001.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360–3365.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226–2229.
   PubMed Web of Science ®Google Scholar
• Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013;98:255–263.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Evans PA, O’Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003;9:2133–2139.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117:2319–2331.
   PubMed Web of Science ®Google Scholar
• Lin P, Medeiros LJ. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica 2007;92:1297–1301.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Miura I, et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777–783.
   PubMed Web of Science ®Google Scholar
• Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009;94:935–943.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273–2279.
   PubMed Web of Science ®Google Scholar
• Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25:145–156.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010;34:327–340.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121: 4021–4031.
   PubMed Web of Science ®Google Scholar
• Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014;165: 382–391.
   PubMed Web of Science ®Google Scholar
• Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112: 3088–3098.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012;119:3668–3683.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529–534.
   PubMed Web of Science ®Google Scholar
• Fiskvik I, Aamot HV, Delabie J, et al. Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. Eur J Haematol 2013;91:332–338.
   PubMed Web of Science ®Google Scholar
• Holte H, Leppa S, Bjorkholm M, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013;24:1385–1392.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Pedersen MO, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience. Eur J Haematol 2012;89: 63–71.
   PubMed Web of Science ®Google Scholar
• Mationg-Kalaw E, Tan LH, Tay K, et al. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology 2012;61:1214–1218.
   PubMed Web of Science ®Google Scholar
• Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013;98:1554–1562.
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121:2253–2263.
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012;7:e33813.
   PubMed Web of Science ®Google Scholar
• Bea S, Colomo L, Lopez-Guillermo A et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004;22:3498–3506.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120: 3986–3996.
   PubMed Web of Science ®Google Scholar
• Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396–4405.
   PubMed Web of Science ®Google Scholar
• Stokke T, DeAngelis P, Smedshammer L, et al. Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin’s lymphoma. Br J Cancer 2001;85:1900–1913.
   PubMed Web of Science ®Google Scholar
• Stokke T, Galteland E, Holte H, et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin’s lymphoma. Int J Cancer 2000;89:313–324.
   PubMed Web of Science ®Google Scholar
• Stokke T, Galteland E, Holte H, et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin’s lymphoma. Int J Cancer 2000;89:313–324.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Moller MB, Tzankov A, et al. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;122:2630–2640.
   PubMed Web of Science ®Google Scholar
• Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res 2010; 16:2435–2442.
   PubMed Web of Science ®Google Scholar
• Howlett C, Goy A, Zielonka T, et al. Dose intensive induction followed by allogeneic stem cell transplantation more than doubles progression-free and overall survival in “double-hit” lymphoma (DHL). Blood 2013;122(Suppl. 1): Abstract 2141.
   Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Concurrent expression of MYC/BCL2 protein in newly diagnosed DLBCL in not associated with an inferior survival following EPOCH-R therapy. Blood 2013;122(Suppl. 1): Abstract 3029.
   Google Scholar
• Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med 2014;65:139–155.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol 2013;4:43–57.
   PubMedGoogle Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904–917.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067–1073.
   PubMed Web of Science ®Google Scholar
• Slaby J, Johnson J, Neri P, et al. Lenalidomide suppresses 5’-cap-independent c-MYC translation in multiple myeloma cells. Blood. 2012;120(Suppl. 1): Abstract 3943.
   Google Scholar